Group Administrators Office
|Canadian Cancer Trials Group CO.17 -- A Phase III Randomized Study of Cetuximab (Erbitux TM, C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR) - Positive Colorectal Carcinoma
Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean EC, Zalcberg JR, Simes J,
Moore MJ, Tebbutt N, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, van Hazel G, Lee U, Haq R, Virk S,
Tu D, Lorimer IAJ. Predictive Biomarkers and Personalized Medicine: PIK3CA, BRAF and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer - results from Canadian Cancer Trials Group / AGITG CO.17. Clin Cancer Res. Online November 11, 2013.
Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, Malone DP, Langer C, Tebbutt N, Price TJ, Shapiro J, Siu LL, Wong RPW, Bjarnason G, Moore MJ, Zalcberg JR, Khambata-Ford S. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer. Online December 12, 2013.
Canadian Cancer Trials Group MAC.4 (IBCSG 24-02) -- A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer
Canadian Cancer Trials Group MAC.5 (IBCSG 25-02) -- A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, Maibach R, Ruepp B, Coates AS, Goldhirsch A, Colleoni M, Gelber RD, Francis PA. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. The Breast 22: 1094-100, 2013.